GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (NAS:SCYX) » Definitions » Earnings per Share (Diluted)

SCYNEXIS (SCYNEXIS) Earnings per Share (Diluted) : $2.02 (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is SCYNEXIS Earnings per Share (Diluted)?

SCYNEXIS's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $2.02.

SCYNEXIS's EPS (Basic) for the three months ended in Mar. 2024 was $0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $2.12.

SCYNEXIS's EPS without NRI for the three months ended in Mar. 2024 was $-0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $1.53.

During the past 12 years, SCYNEXIS's highest 3-Year average EPS without NRI Growth Rate was 53.70% per year. The lowest was 15.70% per year. And the median was 37.15% per year.


SCYNEXIS Earnings per Share (Diluted) Historical Data

The historical data trend for SCYNEXIS's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Earnings per Share (Diluted) Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.58 -5.15 -1.25 -1.47 1.39

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.71 2.46 -0.04 -0.41 0.01

Competitive Comparison of SCYNEXIS's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's PE Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's PE Ratio falls into.



SCYNEXIS Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

SCYNEXIS's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(67.041-0)/48.391
=1.39

SCYNEXIS's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(0.411-0)/48.565
=0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


SCYNEXIS  (NAS:SCYX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


SCYNEXIS Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (SCYNEXIS) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Executives
David C Hastings director C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Brian Philippe Tinmouth director 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Guy Macdonald director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Armando Anido director 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
Scott Sukenick officer: General Counsel 101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Lawrence R Hoffman officer: Interim CFO C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087
Christine Coyne officer: Chief Commercial Officer 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric Francois officer: Chief Financial Officer C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Gonzalez David Angulo officer: Chief Medical Officer C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713